Gastroesophageal Cancer (GC)Postoperative Delirium (POD)Quality of Life (QOL)FrailtyMalnutritionSarcopeniaChemobrainChemotherapyDepression
Study summary
The primary objective of this observational study is to investigate the incidence of Post Operative Delirium (POD) after gastroesophageal cancer surgery. Secondary objectives are to investigate the relationship between POD, preoperative depression, frailty, quality of life, malnutrition and sarcopenia.
Participants identified with POD will be asked (at the routine follow-up meeting after surgery) to participate in an qualitative interview, in order to understand the participant's experience of postoperative delirium.
The main objective aims to answer:
What is the incidence of POD after gastroesophageal cancer surgery.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patients diagnosed with esophageal or gastric cancer, treated with (or without) chemotherapy and surgery.
* Age ≥18 at the time for inclusion.
* Participate on a voluntary basis and can (for any reason) end its participation during the study.
* Capable of giving informed consent.
Exclusion Criteria:
* Patients with preoperative cognitive dysfunction such as dementia.
* Patients who are inoperable due to metastases.
* Patients unable to communicate due to severely impaired hearing and/or - seeing.
* Patients with ongoing drug and/or alcohol abuse.
* Patients who cannot give informed consent.
Primary outcome measure(s)
Incidence of postoperative delirium — From enrollment to the follow up meeting after surgery, approximate 6 months. The assessment of cognitive function will be performed using the validated 4AT Test (4AT).
Cognitive impact will be assessed at baseline before neoadjuvant chemotherapy (if chemotherapy is indicated) and at patient admission for surgery, postoperative day 1, 3 and 7, and at follow-up 4-8 weeks after surgery.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
